From WisPolitics.com/WisBusiness.com …
— Vacancy rates for hospital jobs in Wisconsin have fallen from a recent peak in 2022 but remain well above pre-pandemic levels, a Wisconsin Hospital Association report shows.
The group today released its 2026 Wisconsin Health Care Workforce Report, which shows the state’s hospital vacancy rate was 7.2% on Sept. 30, 2024, the latest date covered in the report. That’s down from 10% on Sept. 30, 2022, but is more than twice as high as in 2019, when the vacancy rate was 3.4%.
Ann Zenk, senior vice president of workforce and clinical practice for WHA, says hospitals are in a “race against time” even as they’re making progress in hiring and retaining workers.
Over the last decade, hospital employment has increased by 23%, the report shows. But overall health care demand is expected to increase 10% by 2040 while the state’s working-age population is shrinking, Zenk said in a statement.
“We’re growing the workforce, but not fast enough to meet the needs of an aging population,” she said.
In addition to putting a strain on the health sector’s workforce, these demographic changes in Wisconsin are causing a shift in reimbursement, which WHA spotlights as a challenge for the industry.
Between fiscal years 2016 and 2024, the share of Medicare in the hospital payer mix increased by 5.3% while commercial insurance fell by 4.9%. The report notes 10,000 baby boomers per day are becoming eligible for Medicare, under which reimbursement falls short of the cost of providing care by 26 cents per dollar.
WHA says a 1% shift from commercial insurance to Medicare could cut hospital revenue in Wisconsin by $286.7 million, based on fiscal year 2024 data.
“Even the most stringent efforts to cut costs or utilization cannot bridge the gap between reimbursement and the cost of providing care, much less provide the investment necessary to grow the infrastructure and workforce to keep pace with increasing health care demand,” authors wrote.
The report includes a number of recommendations aimed at addressing these challenges, such as efforts to “break down barriers” to being part of the health care workforce. Authors point to “legal, regulatory and payer barriers” as a key issue, urging policymakers and others to make reimbursement models and regulations more flexible.
WHA is calling for ensuring the benefit of any new regulations or requirements outweigh the additional work requirement or barriers to access they create before they’re adopted. And the group wants to address insurance company policies and practices that “unnecessarily” delay and deny care at hospitals.
Other recommendations are focused on boosting educational and occupational pathways, to give more students and apprentices opportunities to get connected with employers, as well as encouraging the use of new technologies and models of care.
That includes telehealth monitoring and at-home recovery care, as well as using AI and simulations for education and other programs. WHA is also calling for changes to state law to “relieve bottlenecks” in the continuum of care by supporting patient and family decision-making.
See the report and find the release below.
— A recent study involving Medical College of Wisconsin researchers found “meaningful long-term health risks” linked to certain chemotherapy treatments for testicular cancer.
The study, recently published online in the Journal of the National Comprehensive Cancer Network, explored the impacts of recommended chemotherapy regimens for testicular cancer patients. Researchers looked at outcomes for about 800 long-term cancer survivors treated at eight major cancer centers.
While testicular cancer is the most common form of cancer for men aged 18-39, according to MCW, a treatment called cisplatin-based chemotherapy cures more than 95% of patients.
“Our findings show that while today’s standard chemotherapy regimens are highly effective at curing testicular cancer, they’re associated with meaningful long-term health risks that appear to differ by treatment approach,” said Sarah Kerns, an associate professor of radiation oncology at MCW and a study author.
The study found differences in kidney function, hearing loss and peripheral nerve damage between groups that received different cycles of chemotherapy combinations. Nearly 41% of participants had at least some level of kidney dysfunction, which researchers found to be “strongly associated” with cumulative cisplatin dosing.
Those kidney issues are tied to higher risk of developing hypertension, high cholesterol, and cardiovascular disease.
Meanwhile, researchers also found the chronic health conditions burden was much worse for patients who received more intensive regimens.
MCW says the study results will likely inform national follow-up guidelines for testicular cancer survivors who were treated with cisplatin. Dr. Lois Travis, the study’s senior author and a professor at Indiana University, said the findings “underscore the need for lifelong monitoring” in this population.
“This study demonstrates for the first time that even mild reductions in renal function after chemotherapy can signal elevated later cardiovascular risk in testicular cancer survivors,” Travis said in a statement.
See the release below.
Top Stories
– Hospitals Fighting Measles Confront a Challenge: Few Doctors Have Seen It Before
– US CDC vaccine panel to meet in March after February session scrapped
– Microplastics found in higher levels in prostate tumor tissue: Research
– Trump’s drug pricing claims tested by reality
– Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus
– RFK Jr. says we need more herbicide production, stunning his followers
Press Releases
